HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alternatives to radiotherapy in the management of seminoma.

Abstract
In a period from January 1978 to January 1989, 114 patients with seminoma have been managed, primarily in studies aimed at examining alternatives to radiotherapy. In a pilot study of single agent platinum in 27 previously untreated patients with metastatic seminoma, 82% remain progression-free and 89% alive and disease-free at 5 years compared with 81% progression-free and 88% alive and disease-free in a selected group of 16 previously untreated patients who received platinum-based combination treatment. Results from a pilot study of surveillance in 26 patients with stage 1 seminoma showed that 27% developed evidence of further disease (5 relapses, 2 second tumours) by 3 years, with all relapse patients salvaged by subsequent treatment. Because of the slow pace of relapse compared with malignant teratoma, with relapses occurring after 2 years, a pilot study was initiated to evaluate the effect of 2 courses of adjuvant carboplatin. The results to date in 25 patients suggest that with the use of modern antiemetics this regimen is as well tolerated as prophylactic radiotherapy. With a median follow-up of 16 months there has been 1 relapse subsequently salvaged by combination chemotherapy. A radomised trial is now justified to assess the quality of life and late toxicity of this approach compared with prophylactic radiotherapy.
AuthorsR T Oliver, S Lore, J Ong
JournalBritish journal of urology (Br J Urol) Vol. 65 Issue 1 Pg. 61-7 (Jan 1990) ISSN: 0007-1331 [Print] England
PMID1690070 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Organoplatinum Compounds
  • Bleomycin
  • Vinblastine
  • Carboplatin
  • Cisplatin
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bleomycin (administration & dosage)
  • Carboplatin
  • Cisplatin (administration & dosage, therapeutic use)
  • Dysgerminoma (drug therapy, mortality)
  • Humans
  • Middle Aged
  • Organoplatinum Compounds (administration & dosage, therapeutic use)
  • Prognosis
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: